IVIVA Medicalis a biotechnology startup focused on developing in vivo therapies to treat patients with organ failure. The company received a grant from the Kidney Innovation Accelerator to develop a fully implantable bioartificial kidney.Renal innovation accelerator) issued by the secondReinXRewards. The Kidney Innovation Accelerator is a joint venture between the American Society of NephrologyASN) and the U.S. Department of Health and Human Services (HHS) collaborative public-private partnerships that encourage the use of3DPrinting technology to develop a fully implantable bioartificial kidney. As part of the price,IVIVAwill get100$10,000 in funding to advance research and develop living cell-based therapies that can replace the kidneys’ most fundamental functions.
according toIVIVA MedicalIt is said that all over the world there are8.5Billions of people suffer from kidney disease, including3700Thousands of Americans. In the United States alone, the annual cost of treatment exceeds1000billion dollars. Management and maintenance treatments are ongoing, expensive, and often disruptive to a person’s quality of life. The only hope for these patients is organ transplantation. Unfortunately, the shortage of available organs has led the average patient to put themselves on a waiting list.5Years or more, many died before undergoing surgery.IVIVA MedicalCommitted to changing the status quo by developing fully implantable bioartificial organs that can provide healing and normal life for patients with organ dysfunction.
△IVIVAThe proprietary scaffolding construction technology is developed using3DPrinting to construct finely separated hollow vascular networks
IVIVA MedicalFounder and CEOHarald OttHe said: “Patients with kidney failure experience not only the effects of the disease, but also the unavoidable side effects of existing treatments, as transplanted organs are only available to a lucky few. We are working hard to change the situation of organ transplants. Because we are using patients Our own cells build these implants, so there is no need for long-term immunosuppression, no risk of rejection and no shortage of donor organs. We are delighted to join.ReinXcommunity and acknowledges the support of the Department of Health and Human Services and the American Society of Nephrology. get oneReinXThese awards will help us accelerate the maturation of our technology and improve the lives of patients. “
Developing a fully functional bioartificial kidney has proven difficult in many cases in the past due to the overall complexity of the organ (composed of multiple cell types and performing multiple important functions). Benefit fromReinXprice,IVIVAwill be able to advance technology and address the shortage of organ transplants.
△3Dkidney model
ReinXChairman of the steering committee,BASINMARYLANDJohn R. SedorHe said: “Kidney diseases are common, serious and fatal. People with kidney disease need innovative treatment technologies and care strategies to replace dialysis, which was once50Change happens slowly and gradually over the years. The kidney science community responded with a series of discoveries that promised to revolutionize kidney care. Artificial Kidney Prize II winners highlight the groundbreaking solutions in xenotransplantation and regenerative medicine being developed to reduce the burden of kidney disease. “
Rachel, MD, Assistant Secretary for Health·LAdmiral Levin said: “HHSWe are excited and remain committed to collaborating and advancing kidney care. As the second edition of the Artificial Kidney Prize draws to a close, I have the great pleasure of congratulating the winners of the competition. This competition takes us to a new stage in the development of artificial kidneys, leading to new advances and solutions. “
Source: Antarctic Bear
Daguang focuses on providing solutions such as precision CNC machining services (3-axis, 4-axis, 5-axis machining), CNC milling, 3D printing and rapid prototyping services.
